Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

N.B. Quadriga Candidate Starts Australia Trial for LAT1 Cancers

publication date: Jul 23, 2020

N.B. Quadriga (NBQ) of Shanghai and Nantong announced the first patient has been dosed in a Australian Phase I trial of its novel brain cancer drug. The trial is being conducted by NBQ and its partner, Quadriga Bio of Los Altos, CA. NBQ72S, also known as QBS10072S, is a novel, bi-functional small molecule that targets human LAT1 (L-type amino acid transporter 1), which is highly expressed on the blood-brain barrier and in glioblastoma multiforme along with other aggressive cancers. NBQ uses LAT1-targeting to develop treatments for brain metastases and GBM. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital